Today on The BioHub, I’m joined by Robert Hoffman, Chief Financial Officer of CytoDyn.
Robert is a true industry veteran — with decades ofexperience leading finance and strategy across some of biotech’s most recognizable names, from Arena to Heron and Kintara. Over his career he’s guided IPOs, spin-offs, fundraises, and M&A, all while serving on the boards of multiple biotech companies.
Now at CytoDyn, Robert is helping steer the company as itadvances its lead monoclonal antibody program.
This conversation is about leadership, staying motivated inbiotech’s toughest cycles, and the big vision for CytoDyn’s future.
